NASDAQ: IRON

Disc Medicine Inc Stock Forecast, Predictions & Price Target

The consensus among 6 Wall Street analysts covering (NASDAQ: IRON) stock is to Buy IRON stock.

Out of 6 analysts, 2 (33.33%) are recommending IRON as a Strong Buy, 3 (50%) are recommending IRON as a Buy, 1 (16.67%) are recommending IRON as a Hold, 0 (0%) are recommending IRON as a Sell, and 0 (0%) are recommending IRON as a Strong Sell.

If you're new to stock investing, here's how to buy Disc Medicine stock.

(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.

Disc Medicine's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IRON's revenue for 2026 to be $309,020,825, with the lowest IRON revenue forecast at $309,020,825, and the highest IRON revenue forecast at $309,020,825. On average, 4 Wall Street analysts forecast IRON's revenue for 2027 to be $654,061,117, with the lowest IRON revenue forecast at $88,750,781, and the highest IRON revenue forecast at $914,701,642.

In 2028, IRON is forecast to generate $3,681,970,769 in revenue, with the lowest revenue forecast at $2,224,949,940 and the highest revenue forecast at $5,267,939,808.

According to 6 Wall Street analysts that have issued a 1 year IRON price target, the average IRON price target is $65.17, with the highest IRON stock price forecast at $85.00 and the lowest IRON stock price forecast at $40.00.

On average, Wall Street analysts predict that Disc Medicine's share price could reach $65.17 by May 28, 2025. The average Disc Medicine stock price prediction forecasts a potential upside of 91.95% from the current IRON share price of $33.95.

(NASDAQ: IRON) forecast ROE is N/A, which is considered weak.